je.st
news
Tag: study results
Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
2015-09-18 21:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the companys investigational beta-lactamase inhibitor for the treatment, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), of complicated intra-abdominal infections, met its primary endpoint, and that Merck is now initiating pivotal Phase 3 studies. Language: English Contact: MerckMedia:Doris Li, (908) 246-5701Ian McConnell, (973) 901-5722orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
presented
phase
Trevena Announces Positive Results From Phase 2b Study Of TRV130 In Acute Postoperative Pain
2015-09-02 07:04:14| drugdiscoveryonline News Articles
Trevena, Inc., a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), recently announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery
Tags: results
study
positive
phase
Results From the AMBITION Study of First-Line Treatment With Letairis...
2015-08-27 01:47:44| Biotech - Topix.net
Gilead Sciences, Inc. today announced detailed results from the AMBITION study . In AMBITION, conducted in collaboration with GlaxoSmithKline , combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50 percent compared to the pooled Letairis and tadalafil monotherapy arm .
Tags: with
results
study
treatment
In Interim Results from Phase 3 Study, Mercks Investigational Ebola Vaccine Efficacious; Study is Continuing
2015-07-31 14:10:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Global Collaboration Enabled Vaccine to Move from First-in-Human Studies to Initial Phase 3 Results Within One Year KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558orInvestor Contacts:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Oil & Gas Industry Mangles More Facts, Turns EDF Study Results Upside Down
2015-07-11 05:37:00| Oil & Gas - Topix.net
A new set of peer-reviewed scientific papers pointing to 50 percent higher than estimated regional methane emissions from oil and gas operations in Texas were published this week. And like clockwork, the oil and gas industry's public relations machine, Energy In Depth, proclaimed that rising emissions are actually falling, and that the industry's meager voluntary efforts are responsible.
Tags: results
down
study
industry